Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 13/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | CLK1 | P49759 | 1/20 | 0.50 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.47 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31653956 | 0.84 | PIM1 (0.71) | PIM1CLK1DYRK2 | |
| SCHEMBL7243809 | 0.79 | PIM1 (1.00) | PIM1CLK1DYRK2 | |
| SCHEMBL29696854 | 0.79 | PIM1 (1.00) | PIM1CLK1DYRK2 | |
| SCHEMBL14115819 | 0.79 | PIM1 (1.00) | PIM1CLK1DYRK2 | |
| SCHEMBL31653937 | 0.78 | PIM1 (0.65) | PIM1CLK1DYRK2 | |
| SCHEMBL31653853 | 0.75 | PIM1 (0.67) | PIM1CLK1DYRK2 | |
| SCHEMBL3672518 | 0.73 | PTGS2 (0.75) | MEN1KMT2ANPC1RAB9AHPGD | |
| SCHEMBL3672520 | 0.73 | PTGS2 (0.75) | MEN1KMT2ANPC1RAB9AHPGD | |
| SCHEMBL13535287 | 0.72 | PIM1 (0.76) | PIM1CLK1DYRK2 | |
| SCHEMBL29696944 | 0.72 | PIM1 (1.00) | PIM1CLK1DYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213569-A1 | METHODS AND COMPOSITIONS FOR MEASURING AND INHIBITING EXONUCLEASE ACTIVITY | NEW YORK UNIVERSITY (US) | 2025-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213569-A1 | METHODS AND COMPOSITIONS FOR MEASURING AND INHIBITING EXONUCLEASE ACTIVITY | DCLRE1B, RNASE1, ADAR | PIM1 4605/4885MEN1 3464/4885KMT2A 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.